FindTrial
Sign In

Non-interventional study to analyse the efectiveness and tolerance of chemotherapy with Docetaxel NC(R) or Doce NC (R) during the treatment of breast cancer and prostate cancer as an application for the daily routine

Non-interventional study to analyse the efectiveness and tolerance of chemotherapy with Docetaxel NC(R) or Doce NC (R) during the treatment of breast cancer and prostate cancer as an application for the daily routine

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00004502
Enrollment
450
Registered
2012-12-14
Start date
2012-11-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50 C61

Interventions

Group 1: Patients receive chemotherapy with Docetaxel (Docetaxel NC ® and Doce NC ®) according to the medical prescription, which have breast cancer as a disease. The upraised data of the therapy and

Sponsors

Neocorp GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Histological backed prostate carcinoma or breast cancer, Age over 18 Years, signed patient informed consent, therapy in a practice, which belongs to BNGO or IQUO.

Exclusion criteria

Exclusion criteria: Pregnancy, other malignant diseases in the last 5 years, malignant compliance

Design outcomes

Primary

MeasureTime frame
tolerance evaluated by the NCI CTCAE Criteria—

Secondary

MeasureTime frame
efficacy evaluated by the objective response—

Countries

Germany

Contacts

Public ContactHeribert Stiegler

Onkodatamed GmbH

heribert.stiegler@onkodatamed.de030 / 64 38 75 60

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026